Relatlimab

Records for this ingredient, by country (identity only).

ATC — · 8 markets · 10 records

Relatlimab 8 markets · 10 records Forms
Filters
MarketAU 3US 1GB 1CA 1SG 1EU 1FR 1
Kind

AU 3 records · 2 shown of 2 Source TGA、PBS Schedule API v3 (Department of +1 · Data as of 2026-10-28、live · some records have no stated strength · includes records with unknown status (not proof of sale)

Combination products containing this ingredient

  • 80 mg/20 mLinjection CombinationNivolumab 240 mg/20 mL + Relatlimab 80 mg/20 mLOPDUALAG also in GB
  • 85.2 mg per mL / per unit basis not statedinjection CombinationNivolumab 255.6 mg + Relatlimab 85.2 mgOPDUALAG nivolumab 240mg and relatlimab 80mg in 20mL concentrate solution for IV infusion vial unknown
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
With a brand name Con nombre comercial 有商品名 有商品名OPDUALAG ×2

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包

US 1 records · 1 shown of 1 Source openFDA NDC Directory · Data as of 2026-10-23

Combination products containing this ingredient

  • 4 mg per mL / per unit basis not statedinjection CombinationNivolumab 12 mg + Relatlimab 4 mgOPDUALAG

GB 1 records · 1 shown of 1 Source NHSBSA dm+d · Data as of 2026-10-19

Combination products containing this ingredient

  • 80 mg/20 mLinjection CombinationNivolumab 240 mg/20 mL + Relatlimab 80 mg/20 mLOpdualag 240mg/20ml / 80mg/20ml concentrate for solution for infusion vials also in AU

CA 1 records · 1 shown of 1 Source Health Canada Drug Product Databas · Data as of 2026-10-23

Combination products containing this ingredient

  • 4 mg/1 mLliquid CombinationNivolumab 12 mg/1 mL + Relatlimab 4 mg/1 mLOPDUALAG

SG 1 records · 0 shown of 0 Source Health Sciences Authority (HSA) · Data as of 2026-08-07 · some records have no stated strength

1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
With a brand name Con nombre comercial 有商品名 有商品名OPDUALAG CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/80MG ×1

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包

EU 1 records · 0 shown of 0 Source European Commission · Data as of 2026-11-03 · some records have no stated strength

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
With a brand name Con nombre comercial 有商品名 有商品名OPDUALAG ×2

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包

FR 1 records · 1 shown of 1 Source Base de données publique des médic · Data as of 2026-11-03

Combination products containing this ingredient

  • 4 mg/1 mLinjection CombinationNivolumab 12 mg/1 mL + Relatlimab 4 mg/1 mLOPDUALAG 240 mg/80 mg, solution à diluer pour perfusion

Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.